Linezolid Stada

Linezolid, the active ingredient in Linezolid Stada, is an oxazolidinone antibiotic presented as an oral formulation for oral use. It treats infections caused by susceptible Gram‑positive bacteria, including MRSA and VRE, in adult patients requiring systemic therapy. It is indicated for serious infections where alternative agents may be ineffective.

GNH USA supplies Linezolid Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets European Union quality standards and is manufactured under GMP conditions, ensuring consistent potency and safety for global distribution.

Linezolid is an oxazolidinone antibiotic used to treat a range of serious Gram‑positive bacterial infections.

Complicated skin and soft tissue infections: effective against susceptible Gram‑positive pathogens, helping resolve infection and prevent spread. Community‑acquired bacterial pneumonia: provides bactericidal activity to clear pulmonary infection. Methicillin‑resistant Staphylococcus aureus (MRSA) infections: offers an alternative to vancomycin for resistant strains. Vancomycin‑resistant Enterococcus (VRE) infections: active against VRE where other agents fail. Other infections caused by susceptible Gram‑positive bacteria: broad coverage for various serious Gram‑positive infections.

Linezolid may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset occurring in many patients. - Diarrhea: loose stools that are usually self‑limiting. - Headache: transient cranial discomfort. - Metallic taste: altered taste perception during therapy. - Insomnia: difficulty sleeping reported by some users. - Vomiting: occasional emesis, especially early in treatment.

Serious or Rare Side Effects: - Thrombocytopenia: significant drop in platelet count requiring monitoring. - Anemia: reduction in red blood cells, potentially leading to fatigue. - Peripheral neuropathy: nerve damage causing tingling or numbness. - Serotonin syndrome: risk when combined with serotonergic agents. - Lactic acidosis: rare metabolic disturbance. - Optic neuropathy: vision changes that may be irreversible.

Before initiating therapy, consider patient‑specific factors and monitor for adverse events. - Renal impairment: adjust monitoring as linezolid is partially excreted renally. - Hepatic impairment: monitor liver function tests during treatment. - Concomitant serotonergic drugs: avoid due to risk of serotonin syndrome. - Prolonged therapy (>28 days): monitor complete blood counts for myelosuppression. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Linezolid can interact with several drug classes, requiring caution.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic agents: risk of serotonin syndrome. - Monoamine oxidase inhibitors (MAOIs): increased risk of hypertensive crisis. - Rifampicin: reduces linezolid plasma concentrations, compromising efficacy. - Tyramine‑rich foods: may precipitate hypertensive episodes when combined with MAOI activity.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR; monitor coagulation parameters. - Phenytoin: may lower linezolid levels, reducing effectiveness. - Nephrotoxic drugs: monitor renal function closely during combined use.